A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Clinical trial NCT04239014 · WITHDRAWN
Trial details
- NCT number
- NCT04239014
- Sponsor
- AstraZeneca
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-07
- Primary completion
- 2021-01-25
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.